Proliferative Vitreoretinopathy Prevention Drug Granted Orphan Drug Designation
Tetra Bio-Pharma Inc has received U.S. Food and Drug Administration (FDA) Orphan Drug Designation for its synthetic cannabinoid PPP003 (HU308) for the prevention of proliferative vitreoretinopathy, according to a press release.
“Our research in an experimental model of PVR has demonstrated that the synthetic cannabinoid, PPP003, can prevent this condition through activation of the type 2 cannabinoid receptor. If Tetra’s clinical trial can successfully demonstrate prevention of PVR in humans, PPP003 would become the first prescription eye medication approved for this condition,” said Dr Melanie Kelly CSO, Tetra Bio-Pharma Inc, in the release.
Read the full press release here.